A Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin (PRaCTISe-HR)
A Multi-Centric Parallel Arm Randomized Controlled Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin
This multi-centric RCT across 15 sites in India, tries to evaluates two strategies in order to improve treatment outcomes and reduce recurrences among persons with drug sensitive pulmonary TB (i) Usage of High dose Rifampicin (25mg/kg) given either for 2 months or for 6 months along with other first line anti-TB drugs (ii) Addition of a Fluoroquinolone along with high dose rifampicin to reduce the treatment duration from 6 months to 4 months.
研究概览
地位
条件
详细说明
Trail participants will be monitored for Adverse Drug reactions and clinical and radiological progress weekly during intensive phase and monthly during 1st year follow up and once in 3 months till end of follow up(30th month)
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Dr PK Bhavani, MBBS., MPH., PGDBEME
- 电话号码:044 2836 9537
- 邮箱:bhavani.pk@icmr.gov.in
研究联系人备份
- 姓名:Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
- 电话号码:044 2836 9518
- 邮箱:narendra.ng@icmr.gov.in
学习地点
-
-
Andhra Pradesh
-
Guntur、Andhra Pradesh、印度、522503
- 招聘中
- All India Institute of Medical Sciences(AIIMS), Mangalagiri
-
接触:
- Dr S Sathiyanarayanan, MBBS., MD
- 电话号码:08645 280021
- 邮箱:sathiya@aiimsmangalagiri.edu.in
-
-
Assam
-
Guwahati、Assam、印度、781101
- 主动,不招人
- All India Institute of Medical Sciences, Guwahati
-
-
Gujarat
-
Rajkot、Gujarat、印度、360001
- 尚未招聘
- Govt. PDU Medical College
-
接触:
- Dr Bhoomika Patel, MBBS., MD
- 电话号码:0281 245 8337
- 邮箱:doctorbhoomika@gmail.com
-
Surat、Gujarat、印度、395001
- 主动,不招人
- Govt. Medical College and NCH
-
-
Maharashtra
-
Mumbai、Maharashtra、印度、400008
- 招聘中
- Grant Govt. Medical College & Sir JJ Group of Hospitals
-
接触:
- Dr Priti Meshram, MBBS., MD., DNB
- 电话号码:022 2373 5555
- 邮箱:drpritimeshram@gmail.com
-
Nagpur、Maharashtra、印度
- 尚未招聘
- All India Institute Of Medical Sciences, Nagpur
-
接触:
- Dr Yogesh Bahurupi, MBBS., MD
- 电话号码:0712 2352078
- 邮箱:dr.yogeshab@gmail.com
-
-
Meghālaya
-
Shillong、Meghālaya、印度、793018
- 招聘中
- North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences (NEIGRIHMS)
-
接触:
- Dr Monaliza Lyngdoh, MBBS., MD
- 电话号码:0364 2538013
- 邮箱:monalizalyngdoh@gmail.com
-
-
National Capital Territory of Delhi
-
New Delhi、National Capital Territory of Delhi、印度、110030
- 尚未招聘
- National Institute of TB and Respiratory Diseases
-
接触:
- Dr Jitendra Kumar Saini, MBBS., MD
- 电话号码:011 2651 3325
- 邮箱:drsaini1973@gmail.com
-
-
Odisha
-
Bhubaneswar、Odisha、印度、751019
- 主动,不招人
- All India Institute of Medical Sciences (AIIMS), Bhubaneswar
-
Bhubaneswar、Odisha、印度、751001
- 主动,不招人
- Post Graduate Institute of Medical Education & Research, Capital Hospital
-
-
Tamil Nadu
-
Chennai、Tamil Nadu、印度、600031
- 招聘中
- ICMR - National Institute for Research in Tuberculosis
-
接触:
- Dr PK Bhavani, MBBS., MPH., PGDBEME
- 电话号码:044 2836 9537
- 邮箱:bhavani.pk@icmr.gov.in
-
接触:
- Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
- 电话号码:044 2836 9518
- 邮箱:narendra.ng@icmr.gov.in
-
首席研究员:
- Dr PK Bhavani, MBBS., MPH., PGDBEME
-
首席研究员:
- Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
-
副研究员:
- Dr R Balaji, MBBS., MD.,
-
-
Telangana
-
Hyderabad、Telangana、印度、500038
- 招聘中
- Govt. General and Chest Hospital, Osmania Medical College
-
接触:
- Dr V Karthik, MBBS., MD
- 电话号码:04083814421
- 邮箱:vkarthikrao19@gmail.com
-
-
Uttar Pradesh
-
Agra、Uttar Pradesh、印度、282002
- 招聘中
- Sarojini Naidu Medical College
-
接触:
- Dr Gajendra Vikram Singh, MBBS., MD
- 电话号码:0562 2260353
- 邮箱:drsinghgv@gmail.com
-
Allahābād、Uttar Pradesh、印度、211002
- 招聘中
- Moti Lal Nehru Medical College
-
接触:
- Dr Amitabh Das Shukla, MBBS., MD
- 电话号码:0532 261 3592
- 邮箱:adshukla1977@gmail.com
-
Lucknow、Uttar Pradesh、印度、226003
- 招聘中
- King George Medical University
-
接触:
- Dr Rajiv Garg, MBBS., MD
- 电话号码:0522 2255167
- 邮箱:rajivkgmc@gmail.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Individuals aged equal or above 14 years.
- Symptomatic persons with newly diagnosed sputum positive PTB - smear or NAAT should be positive for Mtb
- Re treatment patients who had previous one episode of microbiologically confirmed (by smear and /or NAAT) pulmonary TB and currently symptomatic and sensitive to all first line anti-TB drugs and quinolones
- If HIV +ve, CD4> 150 cells/mm3 and willing to take ART if not already on it with stable viremia
- Willing to follow the trial procedures
Exclusion Criteria:
-
Body weight less than 30 kg in adults
-
Anti-TB treatment, >14 days for the current illness
-
Known Resistance to rifampicin & Isoniazid at baseline as evidenced by Nucleic acid Amplification test (NAAT) OR LPA
-
Patients with serious forms of Extra-pulmonary TB
-
HIV Patients on second line ART regimens.
-
Baseline Hepatic or renal disease as evidenced by clinical or biochemical abnormalities
- ALT/AST> 2.5 times ULN withTotal bilirubin >2 mg/dl or isolated ALT/AST >5 times ULN (Hy's law criteria)
- Serum Creatinine >1.2 mg/dl.
-
Pregnant or lactating mothers
-
Patients who are seriously ill including symptoms like pneumothorax or hemoptysis with hemodynamic instability
-
Patients with h/o of concomitant medications which may interfere with study drugs
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:2H R25 ZE /4 H R10 E
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol Continuation Phase: Four months of daily conventional dose of Rifampicin(10mg), Isoniazid, and Ethambutol |
Usage of High dose Rifampicin given for 2 months (only during Intensive Phase) along with other first line anti-TB drugs. Usage of High dose Rifampicin given for 6 months (Both Intensive and Continuation Phase) along with other first line anti-TB drugs. |
|
实验性的:2 H R25 ZE/ 4 H R25 E
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol Continuation Phase: Four months of daily treatment with high dose Rifampicin (25mg/kg), Isoniazid, and Ethambutol |
Usage of High dose Rifampicin given for 2 months (only during Intensive Phase) along with other first line anti-TB drugs. Usage of High dose Rifampicin given for 6 months (Both Intensive and Continuation Phase) along with other first line anti-TB drugs. |
|
实验性的:2 H R25 ZE L/2 H R25 E L
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, Ethambutol and Levofloxacin (750/1000mg) Continuation Phase: Two months of daily high dose Rifampicin (25mg/kg), Isoniazid, Ethambutol and Levofloxacin. |
Usage of High dose Rifampicin and Levofloxacin for 4 months along with other first line anti-TB drugs. |
|
有源比较器:2 H R10 ZE /4H R10 E
Intensive Phase: Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol Continuation Phase: Four months of Rifampicin, Isoniazid, and Ethambutol |
Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol and Four months of Rifampicin, Isoniazid, and Ethambutol |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Proportion of patients cured and disease (recurrence) free and alive at 18 months post randomization
大体时间:Cure - At End of Treatment (4 or 6 months) & Recurrence - At 18 months post randomization
|
Cure - At End of Treatment (4 or 6 months) & Recurrence - At 18 months post randomization
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Proportion of patients with grade 3 or 4 adverse drug reactions.
大体时间:Through treatment completion, an average of 24 weeks
|
Through treatment completion, an average of 24 weeks
|
|
|
The proportion of PTB patients who require permanent change of high dose regimen to standard regimen due to adverse events
大体时间:Through treatment completion, an average of 24 weeks
|
Through treatment completion, an average of 24 weeks
|
|
|
The proportion of PTB patients -with smear & culture conversion at end of 2 months & at end of treatment -with radiological clearance at 2 months & at end of treatment
大体时间:At 18 months (Post randomisation) At 2 Years (Post treatment) Both time points are for relapse.
|
At 18 months (Post randomisation) At 2 Years (Post treatment) Both time points are for relapse.
|
|
|
The proportion of patients with drug interactions between the high dose Rifampicin & other first line anti-TB drugs & concomitant medications
大体时间:At 1st Month
|
At 1st Month
|
|
|
The cost effectiveness of different treatment regimens
大体时间:Through treatment completion, an average of 24 weeks
|
Direct and indirect costs incurred by patient, health system and to identify the factors contributing to the cost in the management of TB. |
Through treatment completion, an average of 24 weeks
|
合作者和调查者
调查人员
- 首席研究员:Dr PK Bhavani, MBBS., MPH., PGDBEME、ICMR - National Institute for Research in Tuberculosis
- 首席研究员:Dr G Narendran, MBBS., DNB., DTRD., FRCP.,、ICMR - National Institute for Research in Tuberculosis
出版物和有用的链接
一般刊物
- Kannabiran BP, Arthanari J, Bhaskar A, Narayanan MKS, Inbaraj LR. Efficacy & safety of high-dose rifampicin in pulmonary tuberculosis: A systematic review & meta-analysis. Indian J Med Res. 2025 May;161(5):449-460. doi: 10.25259/IJMR_1673_2024.
- Perumal Kannabiran B, Palaniappan NA, Manoharan T, Paramasivam PK, Saini JK, Ansari MS, Jayabal L, Aggarwal AN, Garg R, Subramanyam B, Thakur D, Pantula S, P M R, Gs V, Natarajan S, Ammayappan RK, Manpreet B, Ganesan M, Angamuthu D, Chinnaiyan P, Singh M, Chandrasekaran P, Swaminathan S. Safety and Efficacy of 25 mg/kg and 35 mg/kg vs 10 mg/kg Rifampicin in Pulmonary TB: A Phase IIb Randomized Controlled Trial. Open Forum Infect Dis. 2024 Feb 2;11(3):ofae034. doi: 10.1093/ofid/ofae034. eCollection 2024 Mar.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 2025 011
- CTRI/2026/02/102698 (注册表标识符:CLINICAL TRIALS REGISTRY - INDIA)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.